Company description
Over the decades BCR signaling has been studied extensively. Deciphering such a complex signaling pathway composed of hundreds of proteins, stimulating dozens of cell reactions has given a significant insight into understanding the biology of lymphoid malignancies. Following those basic discoveries, a number of new drugs targeting pathologic BCR signaling have appeared and many of them are showing excellent clinical properties.
